Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

Trial Profile

Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Pharmacokinetics
  • Acronyms GO-KINETIC

Most Recent Events

  • 01 Jun 2019 Status changed to completed.
  • 24 Oct 2018 Results assessing faecal loss of goli-mumab (n=3) presented at the 26th United European Gastroenterology Week
  • 01 Nov 2017 Results assessing association between systemic exposure of Golimumab during induction therapy and endoscopic response, presented at the 25th United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top